Chuanliang Cui

Chuanliang Cui

UNVERIFIED PROFILE

Are you Chuanliang Cui?   Register this Author

Register author
Chuanliang Cui

Chuanliang Cui

Publications by authors named "Chuanliang Cui"

Are you Chuanliang Cui?   Register this Author

56Publications

1674Reads

19Profile Views

MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways.

Theranostics 2019 25;9(4):945-960. Epub 2019 Jan 25.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing 100142, China.

View Article

Download full-text PDF

Source
http://www.thno.org/v09p0945.htm
Publisher Site
http://dx.doi.org/10.7150/thno.30516DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401396PMC
January 2020

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma.

Clin Cancer Res 2019 Nov 2;25(21):6511-6523. Epub 2019 Aug 2.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-0475DOI Listing
November 2019

Correction to: Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.

J Transl Med 2019 Nov 5;17(1):358. Epub 2019 Nov 5.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Beijing, 100142, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-019-2106-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829941PMC
November 2019

Identification of a functional polymorphism within the 3'-untranslated region of denticleless E3 ubiquitin protein ligase homolog associated with survival in acral melanoma.

Eur J Cancer 2019 Sep 17;118:70-81. Epub 2019 Jul 17.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, 100142, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.06.006DOI Listing
September 2019

Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.

J Transl Med 2019 07 29;17(1):245. Epub 2019 Jul 29.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Beijing, 100142, China.

View Article

Download full-text PDF

Source
https://translational-medicine.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s12967-019-1987-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664769PMC
July 2019

miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy.

J Exp Clin Cancer Res 2019 May 22;38(1):212. Epub 2019 May 22.

Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Beijing, 100142, China.

View Article

Download full-text PDF

Source
https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-
Publisher Site
http://dx.doi.org/10.1186/s13046-019-1190-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532197PMC
May 2019

Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients.

Thorac Cancer 2019 04 12;10(4):950-956. Epub 2019 Mar 12.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Research Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/1759-7714.13034
Publisher Site
http://dx.doi.org/10.1111/1759-7714.13034DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449256PMC
April 2019

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study.

Oncol Res 2019 Mar 3;27(4):495-501. Epub 2018 Aug 3.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, P.R. China.

View Article

Download full-text PDF

Source
http://www.ingentaconnect.com/content/10.3727/096504018X1533
Publisher Site
http://dx.doi.org/10.3727/096504018X15331163433914DOI Listing
March 2019

RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma.

Cell Death Dis 2019 03 15;10(4):254. Epub 2019 Mar 15.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-019-1488-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420644PMC
March 2019

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.

J Hematol Oncol 2019 01 14;12(1). Epub 2019 Jan 14.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer Medicine, Beijing, China.

View Article

Download full-text PDF

Source
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-
Publisher Site
http://dx.doi.org/10.1186/s13045-018-0693-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332582PMC
January 2019

Potential Mutations in Uveal Melanoma Identified Using Targeted Next-Generation Sequencing.

J Cancer 2019 1;10(2):488-493. Epub 2019 Jan 1.

Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, No. 52 Fucheng Road, Haidian District, Beijing, China, 100142.

View Article

Download full-text PDF

Source
http://www.jcancer.org/v10p0488.htm
Publisher Site
http://dx.doi.org/10.7150/jca.26967DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360317PMC
January 2019

Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report.

Chin Clin Oncol 2018 Dec 12;7(6):62. Epub 2018 Jul 12.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2018.06.08DOI Listing
December 2018

Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure.

Transl Oncol 2018 Oct 26;11(5):1155-1159. Epub 2018 Jul 26.

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2018.07.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080644PMC
October 2018

Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study.

Eur J Cancer 2018 09 19;100:1-7. Epub 2018 Jun 19.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.04.007DOI Listing
September 2018

Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients.

Ann Surg Oncol 2018 Aug 10;25(8):2184-2192. Epub 2018 May 10.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-018-6503-9DOI Listing
August 2018

PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.

Cancer Biol Ther 2018 07 30;19(7):584-589. Epub 2018 Apr 30.

a Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma , Peking University Cancer Hospital & Institute , Beijing , China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384047.2018.1435221DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989792PMC
July 2018

copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanoma.

Onco Targets Ther 2018 17;11:4097-4104. Epub 2018 Jul 17.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S158239DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054280PMC
July 2018

High G2 and S-phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis.

Cancer Sci 2018 Jun 11;109(6):1787-1798. Epub 2018 May 11.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cas.13607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989838PMC
June 2018

Gene expression screening identifies CDCA5 as a potential therapeutic target in acral melanoma.

Hum Pathol 2018 05 13;75:137-145. Epub 2018 Feb 13.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00468177183005
Publisher Site
http://dx.doi.org/10.1016/j.humpath.2018.02.009DOI Listing
May 2018

Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China.

Ann Surg Oncol 2018 Apr 21;25(4):885-893. Epub 2017 Dec 21.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Collaborative Innovation Center of Cancer Medicine, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-017-6256-xDOI Listing
April 2018

Increased Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma.

J Cancer 2018 15;9(7):1267-1276. Epub 2018 Mar 15.

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.24013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907675PMC
March 2018

Analysis of TSC1 mutation spectrum in mucosal melanoma.

J Cancer Res Clin Oncol 2018 Feb 28;144(2):257-267. Epub 2017 Nov 28.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Beijing, 100142, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-017-2550-zDOI Listing
February 2018

Clinical significance of BRAF mutation in circulating tumor DNA in Chinese patients with melanoma.

Oncol Lett 2018 Feb 5;15(2):1839-1844. Epub 2017 Dec 5.

Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/ol.2017.7529
Publisher Site
http://dx.doi.org/10.3892/ol.2017.7529DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777120PMC
February 2018

Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.

Eur J Cancer 2018 01 12;89:90-101. Epub 2017 Dec 12.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.11.011DOI Listing
January 2018

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients.

J Hematol Oncol 2018 01 3;11(1). Epub 2018 Jan 3.

Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer Medicine, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing, 100142, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-017-0548-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751546PMC
January 2018

Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy.

J Transl Med 2017 Dec 4;15(1):243. Epub 2017 Dec 4.

Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing, 100142, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12967-017-1344-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716227PMC
December 2017

Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.

Clin Cancer Res 2017 Nov 22;23(22):6946-6957. Epub 2017 Aug 22.

Department of Renal Cancer and Melanoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-17-0070DOI Listing
November 2017

Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon.

Transl Oncol 2017 Oct 12;10(5):719-725. Epub 2017 Jul 12.

Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer Medicine, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Beijing ,100142,China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2017.06.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510521PMC
October 2017

Pathway and Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases.

Clin Cancer Res 2017 Oct 18;23(20):6120-6127. Epub 2017 Jul 18.

The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0980DOI Listing
October 2017

Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma.

Oncol Lett 2017 Sep 19;14(3):3601-3605. Epub 2017 Jul 19.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China.

View Article

Download full-text PDF

Source
https://www.spandidos-publications.com/10.3892/ol.2017.6608
Publisher Site
http://dx.doi.org/10.3892/ol.2017.6608DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587919PMC
September 2017

Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma.

Sci Rep 2017 01 5;7:39597. Epub 2017 Jan 5.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital &Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep39597DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215571PMC
January 2017

GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis.

Eur J Cancer 2016 09 4;65:156-63. Epub 2016 Aug 4.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer Medicine, Beijing, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.06.019DOI Listing
September 2016

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.

Oncotarget 2016 May;7(19):27044-54

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Collaborative Innovation Center for Cancer Medicine, Beijing, China.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053631PMC
http://dx.doi.org/10.18632/oncotarget.7395DOI Listing
May 2016

Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.

Clin Cancer Res 2016 Feb 21;22(4):1018-27. Epub 2015 Oct 21.

The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2015/12/
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-15-1110DOI Listing
February 2016

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition).

Ann Transl Med 2015 Dec;3(21):322

1 Peking University Cancer Hospital & Institute, Beijing 100142, China ; 2 People's Liberation Army (PLA) 81 Hospital, Nanjing 210002, China ; 3 Peking University International Hospital, Beijing 100089, China ; 4 Sun Yat-sen University Cancer Center, Guangzhou 510060, China ; 5 Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing 100730, China ; 6 PLA General Hospital (304 Hospital), Beijing 100048, China ; 7 Zhejiang Provincial Tumor Hospital, Hangzhou 310022, China ; 8 First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 9 Cancer Institute & Hospital, China Academy of Medical Sciences, Beijing 100021, China ; 10 Southwest Hospital & Third Military Medical University Affiliated First Hospital, Chongqing 400038, China ; 11 First Affiliated Hospital of Dalian Medical University, Dalian 116011, China ; 12 Sichuan Provincial People's Hospital, Chengdu 610072, China ; 13 Xi'an Jiao Tong University Affiliated First Hospital, Xi'an 710061, China ; 14 Beijing Jishuitan Hospital & Fourth Clinical College of Peking University, Beijing 100035, China ; 15 Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou 310016, China ; 16 Nineth People's Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China ; 17 Tianjin Medical University Affiliated Tumor Hospital, Tianjin 300321, China ; 18 Jiangsu Provincial People's Hospital & First affiliated hospital of Nanjing Medical University, Nanjing 210036, China ; 19 Yunnan Provincial Tumor Hospital, Nanjing 210029, China ; 20 First Affiliated Hospital of Suzhou University, Suzhou 215006, China ; 21 General Hospital of Jinan Military Command, Jinan 250031, China ; 22 Jilin University First Hospital, Changchun 130021, China ; 23 Southern Hospital, Southern Medical University, Guangzhou 510515, China ; 24 Fudan University Affiliated Tumor Hospital, Shanghai 200032, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2305-5839.2015.12.23DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690993PMC
December 2015

[Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma].

Zhonghua Yi Xue Za Zhi 2015 Aug;95(30):2459-61

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China; Email:

View Article

Download full-text PDF

Source
August 2015

Prognostic factors for conjunctival melanoma: a study in ethnic Chinese patients.

Br J Ophthalmol 2015 Jul 16;99(7):990-6. Epub 2015 Jan 16.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bjophthalmol-2014-305730DOI Listing
July 2015

[A pilot study of sunitinib as first-line therapy for metastatic renal cell carcinoma on a 2 weeks on/1 week off intermittent dosing schedule].

Zhonghua Zhong Liu Za Zhi 2015 May;37(5):375-8

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China; Email:

View Article

Download full-text PDF

Source
May 2015

Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.

Pathol Int 2014 Dec 31;64(12):601-6. Epub 2014 Oct 31.

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/pin.12215
Publisher Site
http://dx.doi.org/10.1111/pin.12215DOI Listing
December 2014

[Genetic polymorphisms of PDGFR associated with thrombocytopenia in Chinese patients with clear-cell metastatic renal cell carcinoma treated with sunitinib].

Zhonghua Yi Xue Za Zhi 2014 Oct;94(38):2988-91

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing 100142, China. Email:

View Article

Download full-text PDF

Source
October 2014

[Impact of sequential targeted therapy on progression-free survival in metastatic renal cell carcinoma].

Zhonghua Yi Xue Za Zhi 2014 Sep;94(33):2580-3

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Kidney Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing 100142, China. Email:

View Article

Download full-text PDF

Source
September 2014

Chemotherapy, biochemotherapy and anti-VEGF therapy in metastatic mucosal melanoma.

Chin Clin Oncol 2014 Sep;3(3):36

The Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2304-3865.2014.07.02DOI Listing
September 2014

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.

BMC Cancer 2014 May 28;14:376. Epub 2014 May 28.

Department of Renal Cancer and Melanoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing 100142, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-14-376DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041340PMC
May 2014

Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.

Clin Cancer Res 2013 Dec 16;19(24):6935-42. Epub 2013 Oct 16.

Authors' Affiliations: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China; and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-1266DOI Listing
December 2013

Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.

Clin Cancer Res 2013 Aug 5;19(16):4488-98. Epub 2013 Jul 5.

Department of Renal Cancer and Melanoma, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0739DOI Listing
August 2013

A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma.

Mol Ther 2013 Jul 14;21(7):1456-63. Epub 2013 May 14.

Department of Renal Cancer and Melanoma, The Key laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/mt.2013.79DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702105PMC
July 2013

Major response to everolimus in melanoma with acquired imatinib resistance.

J Clin Oncol 2012 Feb 12;30(4):e37-40. Epub 2011 Dec 12.

Peking University Cancer Hospital and Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.37.9644DOI Listing
February 2012

Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.

Eur J Cancer 2012 Jan 23;48(1):94-100. Epub 2011 Jul 23.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2011.06.056DOI Listing
January 2012

A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients.

Eur J Cancer 2011 Jul 13;47(10):1498-503. Epub 2011 Apr 13.

Department of Melanoma and Renal Cancer, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2011.03.019DOI Listing
July 2011

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

J Clin Oncol 2011 Jul 20;29(21):2904-9. Epub 2011 Jun 20.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.33.9275DOI Listing
July 2011

Large-scale analysis of KIT aberrations in Chinese patients with melanoma.

Clin Cancer Res 2011 Apr 15;17(7):1684-91. Epub 2011 Feb 15.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-10-2346DOI Listing
April 2011

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases.

BMC Cancer 2011 Feb 25;11:85. Epub 2011 Feb 25.

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-11-85DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056833PMC
February 2011